论文部分内容阅读
目的研究B细胞非霍奇金淋巴瘤运用利妥昔单抗注射液联合化疗治疗的临床效果。方法 128例B细胞非霍奇金淋巴瘤患者,将其随机分为对照组和观察组,各64例。对照组患者采用单纯性CHOP方案进行化疗,观察组患者采用利妥昔单抗注射液联合化疗的方法进行治疗,比较两组患者的临床治疗效果。结果观察组总有效率90.63%高于对照组71.88%,差异有统计学意义(P<0.05);两组患者治疗过程中出现不良反应的情况比较,差异无统计学意义(P>0.05)。结论对B细胞非霍奇金淋巴瘤实施治疗时,选择利妥昔单抗注射液联合化疗治疗的临床效果显著,同时患者具有很好的耐受性,毒副作用不明显,适合在临床上推广使用。
Objective To study the clinical effect of Rituximab injection and chemotherapy in B cell non-Hodgkin’s lymphoma. Methods 128 patients with B cell non-Hodgkin’s lymphoma were randomly divided into control group and observation group, with 64 cases in each group. Patients in the control group were treated with simple CHOP chemotherapy. The patients in the observation group were treated with rituximab injection combined with chemotherapy, and the clinical effects of the two groups were compared. Results The total effective rate in the observation group was 90.63%, which was significantly higher than that in the control group (71.88%) (P <0.05). There was no significant difference between the two groups in adverse reactions during treatment (P> 0.05). Conclusion When treating B cell non-Hodgkin’s lymphoma, the clinical effect of combining rituximab injection and chemotherapy is significant, and the patients have good tolerance and little toxic and side effects, which is suitable for clinical promotion use.